Drug Trial Radar · NCT00003615
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Planned (sponsor's estimate)
Start
May 20, 1999
Primary completion
Aug 2006
Sponsor
- Lead sponsor
- Eastern Cooperative Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Feb 20, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin's lymphoma that has not responded to previous treatment.
Conditions
- Lymphoma
Interventions
denileukin diftitoxBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois
Beth Israel Deaconess Medical Center
Boston, Massachusetts
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada
Trinitas Hospital - Jersey Street Campus
Elizabeth, New Jersey
Hunterdon Regional Cancer Center
Flemington, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey
Morristown Memorial Hospital
Morristown, New Jersey
Riverview Medical Center - Booker Cancer Center
Red Bank, New Jersey
Overlook Hospital
Summit, New Jersey
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.